Crossmark

Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report

Crossref DOI link: https://doi.org/10.1007/s40620-024-02182-5

Published Online: 2025-01-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ollé, Julia

Larque, Ana Belen

de Larrea, Carlos Fernandez

Diekmann, Fritz

Cucchiari, David
License Information

Text and Data Mining valid from 2025-01-14

Version of Record valid from 2025-01-14
More Information

Article History

Received: 27 September 2024

Accepted: 27 November 2024

First Online: 14 January 2025

Declarations

:

: DC received speakers’ fees from GSK, Astellas, Chiesi and CareDx and research grant from CareDx, FD has received speaker’s fees and research grant from CareDx and Hansa. CFL declares receiving grants throughhis institution from BMS, Janssen, and Amgen; honoraria from Amgen, Janssen, BMS, GSK and Sanofi; support forattending meetings or travel from Janssen, BMS, GSK andAmgen; and participation in data safety monitoring or ad-visory boards with Janssen, BMS, Amgen, Pfizer and Sanofi. The other authors have not conflict of interests to disclose.

: No ethical approval is needed by our Institution for the publication of Case Reports.

: All the procedures were approved by the Hospital Clínic of Barcelona.

: The patient provided informed consent to publish his anonymized data.

Document is current

Any future updates will be listed below